Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: A real-world registry
出版年份 2023 全文链接
标题
Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: A real-world registry
作者
关键词
-
出版物
ATHEROSCLEROSIS
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2023-03-30
DOI
10.1016/j.atherosclerosis.2023.03.013
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Sex differences in low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real world patients
- (2022) Alberto Cordero et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Sex difference in circulating PCSK9 and its clinical implications
- (2022) Fang Jia et al. Frontiers in Pharmacology
- Sex differences in LDL-C response to PCSK9 inhibitors: A real world experience
- (2022) Martine Paquette et al. Journal of Clinical Lipidology
- Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease
- (2021) Elias J. Dayoub et al. Journal of the American Heart Association
- Increasing Participation of Women in Cardiovascular Trials
- (2021) Leslie Cho et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
- (2021) Juan Vicente-Valor et al. BIOMEDICINE & PHARMACOTHERAPY
- Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction
- (2021) EC McKinley et al. Journal of Clinical Lipidology
- LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
- (2020) Peter Sever et al. European Journal of Preventive Cardiology
- 17β-Estradiol Inhibits PCSK9-Mediated LDLR Degradation Through GPER/PLC Activation in HepG2 Cells
- (2020) Wei Fu et al. Frontiers in Endocrinology
- Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE Study
- (2020) Nicola Ferri et al. ATHEROSCLEROSIS
- Efficacy and tolerability of alirocumab in Austrian clinical practice – results of the non-interventional PEARL-AT study
- (2020) Deborah R. Leitner et al. CURRENT MEDICAL RESEARCH AND OPINION
- Participation of Women and Older Participants in Randomized Clinical Trials of Lipid-Lowering Therapies
- (2020) Safi U. Khan et al. JAMA Network Open
- Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
- (2020) Gregory A. Roth et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Evolocumab on Low‐Density Lipoprotein Cholesterol, Non–High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta‐Analysis of Individual Participant Data From Double‐Blind and Open‐Label Extension Studies
- (2020) Martha L. Daviglus et al. Journal of the American Heart Association
- Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study
- (2019) Tim Hollstein et al. VASCULAR PHARMACOLOGY
- Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes
- (2019) Kelly D. Myers et al.
- Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
- (2019) Salim Yusuf et al. LANCET
- P5367Indirect comparison of the safety and efficacy of alirocumab and evolocumab: from a comprehensive meta-analysis of 30 randomized controlled trials
- (2019) P Guedeney et al. EUROPEAN HEART JOURNAL
- Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (The Mayo Clinic Experience)
- (2019) Ohad Oren et al. AMERICAN JOURNAL OF CARDIOLOGY
- PCSK9 Inhibitors’ New Users: Analysis of Prescription Patterns and Patients’ Characteristics from an Italian Real-world Study
- (2019) Carlo Piccinni et al. CLINICAL DRUG INVESTIGATION
- Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials
- (2018) Antonio J. Vallejo‐Vaz et al. Journal of the American Heart Association
- Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
- (2018) Lawrence Blonde et al. ADVANCES IN THERAPY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience
- (2017) Annette M.H. Galema-Boers et al. Journal of Clinical Lipidology
- Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials
- (2017) Aris Karatasakis et al. Journal of the American Heart Association
- Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry
- (2016) Rodrigo Alonso et al. Journal of Clinical Lipidology
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol
- (2014) Moumita Ghosh et al. JOURNAL OF LIPID RESEARCH
- Underrepresentation of Women, Elderly Patients, and Racial Minorities in the Randomized Trials Used for Cardiovascular Guidelines
- (2014) Muhammad Rizwan Sardar et al. JAMA Internal Medicine
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started